about
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisSomatic mutations of calreticulin in myeloproliferative neoplasms.Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab" population-based study.Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysisAmbient air pollution and adult asthma incidence in six European cohorts (ESCAPE).Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasmsIs drop-out from obesity treatment a predictable and preventable event?Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana LinfomiJAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.Cross-sectional associations between air pollution and chronic bronchitis: an ESCAPE meta-analysis across five cohorts.Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.Influence of socio-demographic features and apolipoprotein E epsilon 4 expression on the prevalence of dementia and cognitive impairment in a population of 70-74-year olds: the InveCe.Ab study.Psychological care of caregivers, nurses and physicians: a study of a new approach.Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study.Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia.Epidemiology of multiple sclerosis in south-western Sardinia.Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry.Monoclonal gammopathy of undetermined significance: a new proposal of workup.Nonexpanded mesenchymal stem cells for regenerative medicine: yield in stromal vascular fraction from adipose tissues.Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.Epidemiology and geographical variation of myasthenia gravis in the province of Pavia, Italy.Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomasCALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosisBone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathiesICA-EMA: A Tool for Assessing Nursing Complexity of Patients With Oncohematologic Disease in an Italian Center
P50
Q33416223-A8144E14-FBB6-4CF9-AD4C-8D635DB7A11FQ34039270-AAC48FFB-52EF-40C5-AA11-282AF89344C9Q34996345-1B0B411B-40AE-4226-B208-FD9856BEC313Q35009935-EA33FF9D-8D56-48E4-B225-0EDD399BA0CAQ35683219-BC209412-1911-4A22-AEAA-88304922CFB7Q36541323-C6E79F0B-E798-4A63-B028-E21EC11BCC09Q36715896-2E1B2E48-FA39-4E83-9616-40444FF4EA72Q36873306-A6E5B6A5-AEF8-4669-A888-F6457933C38BQ37558157-14B6841A-DF85-4B1F-AFDD-4154196430D1Q37618904-19CFE4B5-CA6C-438C-A939-8EB54FF3E573Q37623539-D40E4D2A-1C8A-4343-A088-764E163BDD3DQ38220788-66998B54-50F8-4AEC-AD96-CC65C41CA160Q38238955-2E94E7D6-4A3E-4C7E-B23E-DC548031F14AQ38878808-19DC79AC-820D-4285-B808-33E928CF8E01Q38878814-924F2164-2378-422B-9F1C-94690613435AQ41696221-020383EA-0734-40EA-AB40-0E6506590A2BQ41736005-06CBF71D-64E6-4D9E-B692-E6DB2A2ED2F3Q41968577-DE28D105-4039-4D67-91D1-15CB33901677Q42476592-F0EE57BD-D401-48CC-9845-DACFEC2D5CAAQ42758710-9281A7A1-EEAC-44C7-B9E2-596DE4A89960Q43556532-B660028F-C128-42B4-9C1A-F9754A1CE573Q44119338-08ABADB0-F0F3-4E2E-88A0-E6579765F45FQ44580273-8EE89A51-6DCA-490B-A6EF-312CDE5EEFF5Q45859236-35E4C648-DB30-4458-B10A-6C28044580A8Q46057559-3D2CE523-8EFF-4296-9A32-0D433BFCA7D7Q46693258-8003481F-F279-49C8-8835-3E9723D618F5Q50960713-9120E896-0E29-497D-8725-D6E0C16DA52AQ53008520-70CF1622-D447-4537-AA24-129C62296D14Q57718877-1EDFD756-2302-400A-AD0D-1F8086ADF72CQ61758700-243E4E1B-D6A2-4185-87FD-B9C14E588F41Q85233241-DCE54FD1-B472-4BF9-BF4D-DE1DD945AA55Q91996289-ACE4B456-E2C8-49DE-BCA7-2AC13A69786A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Virginia Ferretti
@ast
Virginia Ferretti
@en
Virginia Ferretti
@es
Virginia Ferretti
@nl
Virginia Ferretti
@sl
type
label
Virginia Ferretti
@ast
Virginia Ferretti
@en
Virginia Ferretti
@es
Virginia Ferretti
@nl
Virginia Ferretti
@sl
prefLabel
Virginia Ferretti
@ast
Virginia Ferretti
@en
Virginia Ferretti
@es
Virginia Ferretti
@nl
Virginia Ferretti
@sl
P106
P1153
35302119900
P21
P31
P496
0000-0003-0130-915X